logo-loader
CelLBxHealth PLC

Cellbxhealth PLC - Further Update on Funding

RNS Number : 3856G
Cellbxhealth PLC
05 November 2025
 

NOT FOR DISTRIBUTION INTO THE UNITED STATES

 

The information contained in this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States.  The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, resold, transferred, delivered or distributed, directly or indirectly, in any form, in or into, the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. No public offering or sale of securities in the United States will be made.

 

 

CELLBXHEALTH plc ("the Company")

 

Further Update on Funding

 

CELLBXHEALTH plc (AIM:CLBX), a global leader in circulating tumour cell (CTC) intelligence, announces, further to the interim results of 9 October 2025, the Company currently has a cash runway into early 2026.  CelLBxHealth has recently commenced discussions with a number of shareholders and is seeking to raise approximately £6m with the intention to make an offer to retail investors alongside an institutional placing.  

 

The Company expects to announce the fundraise by early December and will make further updates as appropriate.  

 

For further information:

 

CelLBxHealth plc

+44 (0) 1483 343434

Peter Collins, Chief Executive Officer

 investor@CelLBxHealth.com

 

Cavendish (NOMAD and Broker)

Geoff Nash / Isaac Hooper (Corporate Finance)

Sunila de Silva (Corporate Broking)

Nigel Birks (Life Science Specialist Sales)

 

+44 (0) 20 7220 0500

 

FTI Consulting

Simon Conway, Ciara Martin, Sam Purewal

 

 

 

+44 (0) 203 727 1000

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014). Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

 Notes for editors

 

About CelLBxHealth plc

CelLBxHealth plc is a global precision CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be seamlessly integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.

 

Commercial activities centre on (1) Product Sales:  Accelerating Parsortix platform adoption and consumable sales through CROs* and clinical lab partnerships. (2) Lab Developed Tests (LDTs): Strategic partnerships combined with a focused in-house development programme (3) Laboratory services: Clinical trial support and assay development.

 

The product portfolio comprises the Parsortix® platform with associated consumables and assays. Laboratory services are delivered from CelLBxHealth's GCLP certified UK laboratory, providing bespoke clinical-trial support and assay development.

 

For more information, visit https://cellbxhealth.com/.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURUVRWRVWUARAA
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

London BTC Company, CelLBxHealth, Anglo Asian Mining, Galliford Try,...

London BTC Company Ltd (LSE:BTC, OTCQB:VINZF) has staked 36 mineral claims at its new Black Star gold-silver project in Nevada, with surface samples returning up to 16.23 grams per tonne gold. It's the company's fourth Nevada project and sits just 16 miles from the 16.4 million ounce Hycroft...

on 07/15/2026

3 min read